Bishnoi Dental Care has conducted 1,000+ outreach camps in Rajasthan, screening 40,000 rural patients and improving dental ...

A study published in Cancer Letters by researchers from the University of Louisville found that a specially designed oral CBD formulation significantly improved tumor targeting and slowed the growth ...

Shares in Roche dropped more than 5% on Monday as the Swiss drugmaker failed to show that its promising drug candidate ...

Bristol Myers Squibb said its treatment candidate for certain blood cancers performed well in a late-stage trial.

Roche's shares dropped more than 5% on Monday as the ​Swiss drugmaker failed to show that its promising breast cancer drug ...

Roquefort Therapeutics is acquiring exclusive worldwide rights to a clinical-stage tumour inhibitor for £32m in an all-paper deal and raising £8.5 million.

AstraZeneca has also filed an oral SERD, camizestrant, targeting use of the drug in patients with advanced HR-positive breast ...

A phase 3 trial of Roche’s giredestrant in first-line breast cancer patients has missed its primary endpoint, tarnishing the record of a drug that hit the mark in adjuvant and second-line settings.

Bristol Myers Squibb on Monday said its experimental drug for a rare form ​of blood cancer improved survival in a late‑stage ...

Roche shares have dropped after its oral breast cancer drug giredestrant failed to show benefits in a key phase III clinical ...

Roche's shares dropped more than 7% at one stage on Monday, their biggest ​decline in nearly a year, after the Swiss ...

A breakthrough AI system is revolutionizing cancer immunotherapy by enabling scientists to design protein-based keys that train a patient s immune cells to attack cancer with extreme precision. This ...